Physician
Endocrinology
Dr. Mark S. Kipnes, MD
|
|
Give Review
Mark Kipnes is an expert in the field of Endocrinology. He studied medicine at Drexel University College of Medicine. He received awards:"Super Doctor" and "Top MD". Mark S. Kipnes, MD is a published physician. He has 41 papers published. The most current publication "Domperidone in the management of symptoms of diabetic gastroparesis: efficacy, tolerability, and quality-of-life outcomes in a multicenter controlled trial. DOM-USA-5 ..." He is registered with Medicare and accepts Medicare payments.
Publications
- Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 Diabetes and nonalcoholic fatty liver disease.
- Macimorelin (AEZS-130)-stimulated growth hormone (GH) test: validation of a novel oral stimulation test for the diagnosis of adult GH Deficiency.
- A long-acting human growth hormone With delayed clearance (VRS-317): Results of a double-blind, placebo-controlled, single ascending dose study in growth hormone defic...
- A 16-week open-label, multicenter pilot study assessing insulin pump therapy in patients with type 2 Diabetes suboptimally controlled with multiple daily injections.
- Insulin pump therapy in patients with type 2 Diabetes safely improved glycemic control using a simple insulin dosing regimen.
- Single-dose pharmacokinetics and pharmacodynamics of sergliflozin etabonate, a novel inhibitor of glucose reabsorption, in healthy volunteers and patients with Type 2 ...
- Clinical performance of the TRUE2go blood glucose system--a novel integrated system for meter and strips.
- Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients ...
- Efficacy of eplerenone versus enalapril as monotherapy in systemic hypertension.
- Glycemic and insulinemic responses of nonDiabetic healthy adult subjects to an experimental acid-induced viscosity complex incorporated into a glucose beverage.
- Dose response of subcutaneous GLP-1 infusion in patients with type 2 Diabetes.
- Year two assessment of fenofibric acid and moderate-dose statin combination: a phase 3, open-label, extension study.
- A one-year study to assess the safety and efficacy of the CB1R inverse agonist taranabant in overweight and obese patients with type 2 Diabetes.
- Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 Diabetes inadequately controlled by glyburide monotherapy.
- Sitagliptin: a viewpoint by Mark S. Kipnes.
- Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 Diabetes.
- Effects of pioglitazone on lipid and lipoprotein profiles in patients with type 2 Diabetes and dyslipidaemia after treatment conversion from rosiglitazone while contin...
- Immunomodulation in type 1 Diabetes by NBI-6024, an altered peptide ligand of the insulin B epitope.
- Short-term pharmacokinetic comparison of a novel testosterone buccal system and a testosterone gel in testosterone deficient men.
- Effects of simvastatin on the lipid profile and attainment of low-density lipoprotein cholesterol goals when added to thiazolidinedione therapy in patients with Type 2...
- Testosterone pharmacokinetics after application of an investigational transdermal system in hypogonadal men.
- Adverse effects of recombinant human insulin-like growth factor I in obese insulin-resistant Type II diabetic patients.
- Effects of short-term insulin therapy upon therapeutic response to glipizide.
- Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with type 2 Diabetes mellitus: a randomized, placebo-controll...
- Sugar-free zinc gluconate glycine lozenges (Cold-Eeze) do not adversely affect glucose control in patients with type 1 or type 2 Diabetes mellitus.
- Domperidone in the management of symptoms of Diabetic gastroparesis: efficacy, tolerability, and quality-of-life outcomes in a multicenter controlled trial. DOM-USA-5 ...
- Control of postprandial plasma glucose by an oral insulin product (HIM2) in patients with type 2 Diabetes.
- Striant SR: a novel, effective and convenient testosterone therapy for male hypogonadism.
- The impact of insulin glargine on clinical and humanistic outcomes in patients uncontrolled on other insulin and oral agents: an office-based naturalistic study.
- New testosterone buccal system (Striant) delivers physiological testosterone levels: pharmacokinetics study in hypogonadal men.
- Differences in glucose tolerance between fixed-dose antihypertensive drug combinations in people With metabolic syndrome.
- Tolerability and pharmacokinetics of metformin and the dipeptidyl peptidase-4 inhibitor sitagliptin when co-administered in patients with type 2 Diabetes.
- Safety and effectiveness of Realize adjustable gastric band: 3-year prospective study in the United States.
- Dapagliflozin: an emerging treatment option in type 2 Diabetes.
- Evaluation of various doses of recombinant human thyrotropin in patients With multinodular goiters.
- Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 Diabetes mellitus inadequately controlled on glimepiride alone or on ...
- Gastric electrical stimulation with the TANTALUS System in obese type 2 Diabetes patients: effect on weight and glycemic control.
- Sitagliptin: a review.
- Comparison of insulin lispro protamine suspension and insulin detemir in basal-bolus therapy in patients with Type 1 Diabetes.
- Efficacy and Safety of Taspoglutide Monotherapy in Drug-Naive Type 2 Diabetic Patients After 24 Weeks of Treatment: Results of a randomized, double-blind, placebo-cont...
Schools
Drexel University College of Medicine
Procedures Preformed
- Continuous Glucose Monitoring
Conditions Treated
- Abnormal Thyroid
- Adrenal Insufficiency
- Adrenogenital Disorders
- Calcium Metabolism Disorders
- View All
Doctors Specialties
- Endocrinology
Accepted Insurances
Awards
- Super Doctor
- Top MD
Education
-
George Washington University -
University of Pittsburgh Medical Center-Mercy Hospital -
Drexel University College of Medicine
Hospital
-
CHRISTUS Santa Rosa Health System
Drug Facts
| NPI NUMBER | 1376501965 | |
| NPPES Provider LastName | KIPNES | |
| NPPES Provider FirstName | MARK | |
| NPPES Provider ZIPCode | 78229 | |
| NPPES Provider State | TX | |
| Specialty Description | Endocrinology | |
| Total Claim Count | 5753.0 | |
| Distinct Opioid Count | 2.0 | |
| Opioid Claim Count | 46.0 | |
| Percent Opioid Claims | 0.8 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1376501965 |
| Last Name Of The Provider | KIPNES |
| First Name Of The Provider | MARK |
| View All |
Similar Doctors
|
|
Dr. Mark M. Danney, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Forest P. Newman III, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jan M. Bruder, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Sam S. Miller, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ramon Garza, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. William F. Trigoso, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Amna A. Salhin, MD
This Doctor is OpenDoctor Recommended.
|